US 12,290,514 B2
Therapeutic agent for bile duct cancer
Tatsuhiro Shibata, Tokyo (JP); Yasuhito Arai, Tokyo (JP); Kenichi Nomoto, Andover, MA (US); Tomio Nakamura, Tokyo (JP); Akihiko Tsuruoka, Tokyo (JP); and Saori Miyano, Tsukuba (JP)
Assigned to National Cancer Center, Tokyo (JP); and Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed by NATIONAL CANCER CENTER, Tokyo (JP); and Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed on Dec. 19, 2018, as Appl. No. 16/225,772.
Application 16/225,772 is a continuation of application No. 15/547,139, previously published as PCT/JP2016/059162, filed on Mar. 23, 2016.
Claims priority of provisional application 62/138,058, filed on Mar. 25, 2015.
Prior Publication US 2019/0111043 A1, Apr. 18, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4545 (2006.01); A61P 1/16 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4545 (2013.01) 9 Claims
 
1. A method for treating a bile duct cancer in a patient having a gene encoding an FGFR 2-fusion protein, comprising administering to the patient a pharmacologically effective amount of 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide or a pharmaceutically acceptable salt thereof.